jmeilink, Don't be so hard on yourself. An inexorable mental decline is merely part of the aging process. In your case, it seems to be occurring at an accelerated pace.
""DNDN is best stock in next months,i think the best move is long with the pearl DNDN ""
Thanks for the laugh.
syenfrout, spot on target. SNTA's fortunes are completely linked to the success or failure of Ganetespib. That will change only AFTER they get several HSP90i drug conjugates into clinical trials. Of course, a partnership deal could significantly improve the SNTA stock price, but that will be also be driven by the success or failure of Ganetespib.
Just to be clear, my "you are a pathetic persons" comment was directed at jmeilink6000.
Why are you looking at the DOW? If you want to make moronic comments, at least compare PGNX to the NASDAQ.
I don't know what not showing at the investor conference is about, but I doubt very much it is related to the ADCOM board.
The best reason for us would be #2, but more likely we will be the ones nursing a hangover soon as the market will likely not view this as favorable development for PGNX.
Did you mean the final results for Galaxy I, the phase II trials for NSCLC? If so, where is the link?
Yes more than a nice bump. As far as estimating valuation, sddawg brought up an estimate for the PGNX imaging agent, which was based on how many how new prostate cancer cases are diagnosed each year. What we need to get to begin to generate some kind of estimate for its valuation is 1) how many of these new patients get an MRI, 2) who many previously diagnosed patients get an MRI and when in the course of the disease progression it is likely to be used. Is it when changes in PSA are detected?, 4) do patients get follow-up MRIs to evaluate if their treatments are working. 5) how many MRIs do patients normally get?, 6) how much an MRI costs, to give us an idea of prancing power for the imaging agent, 7) what kind of market penetrance PGNX expects to get and how quickly they expect to achieve that. I recognize it is early, but PGNX could at least give some hints at what this means for shareholders and their expectations. This is the area at which PGNX management fails miserably.
carlrich, I see you found the article about the offering. It is worth it to mention that SNTA raised $60 million using that.
Nice try sddawg by trying to deflect attention from your own errors by attacking me. I never made any comments regarding your valuations of PGNX. As to whether PGNX is a good investment at current prices, who knows, but I think it has a shot at getting a nice bump if the FDA does grant label expansion. If not, it will drop. Your speculations are just as speculative as mine.
Entereg and Relistor are NOT similar drugs. I read that comment of yours quite clearly and it is wrong. Yes they are both designed to inhibit the mu-opoid receptors, but different drugs have different off-target effects, and even drugs that target the same have different effects and different toxicities due to their effects specifically on that receptor. Entereg showed statistical significance in post-operative ileus (POI), which is where it got FDA approval, whereas Relistor failed in that indication. The issue of CVs were THOUGHT to occur based on counteracting opiates, where the block of mu-opiod receptors is essentially equivalent to a quick withdrawal of opiates. But a direct effect of Entereg on the mu-opiod receptor may have contributed. The increased neoplasia seen in Entereg use is what sank it for broader uses.
I have never said that Relistor expansion into chronic pain was a certainty. It is a risk, which is why the PGNX stock price is so low.
sddawg, Entereg also had issues with neoplasias being found in patients at higher rates that controls. The FDA restrictions on Entereg are quite severe, but Relistor has nothing remotely close. Quite frankly, I am beginning to think you are a short coming here to sow misinformation, so I doubt you and you motives for being here.